Results 191 to 200 of about 257,683 (336)

Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple‐Class‐Exposed Relapsed/Refractory Multiple Myeloma

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Idecabtagene vicleucel (ide‐cel, ABECMA) is an autologous, B‐cell maturation antigen‐directed, chimeric antigen receptor (CAR) T‐cell therapy, which has demonstrated significantly improved progression‐free survival (PFS) and overall response rate (ORR) in patients with triple‐class‐exposed relapsed/refractory multiple myeloma (TCE RRMM). Here,
Fan Wu   +11 more
wiley   +1 more source

Effect of cyclophosphamide on the response of chickens to a virulent strain of Marek's disease virus [PDF]

open access: bronze, 1975
Vali Kermani-Arab   +4 more
openalex   +1 more source

Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Recognition of benefits and adverse effects of therapies in earlier clinical trial phases could improve the safety, efficiency, and cost of clinical trials. Using four clinical trials representing a diverse set of diseases and drug classes (EXSCEL: exenatide/GLP‐1 RA, SUGAR‐DM‐HF: empagliflozin/SGLT2i, PRADA: epirubicin/anthracycline, and ...
Jessica Chadwick   +17 more
wiley   +1 more source

Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis

open access: green, 1976
Ellen M. Ginzler   +3 more
openalex   +1 more source

Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer

open access: yesClinical Cancer Research, 2017
M. Scurr   +15 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy